All Outputs (5)

Discovery of a Novel Polymer for Xeno-Free, Long-Term Culture of Human Pluripotent Stem Cell Expansion (2020)
Journal Article
Nasir, A., Thorpe, J., Burroughs, L., Meurs, J., Pijuan‐Galito, S., Irvine, D. J., …Denning, C. (2020). Discovery of a Novel Polymer for Xeno-Free, Long-Term Culture of Human Pluripotent Stem Cell Expansion. Advanced Healthcare Materials, 10(6), Article 2001448. https://doi.org/10.1002/adhm.202001448

Human pluripotent stem cells (hPSCs) can be expanded and differentiated in vitro into almost any adult tissue cell type, and thus have great potential as a source for cell therapies with biomedical application. In this study, a fully-defined polymer... Read More about Discovery of a Novel Polymer for Xeno-Free, Long-Term Culture of Human Pluripotent Stem Cell Expansion.

CRISPR/Cas9-mediated generation and analysis of N terminus polymorphic models of ?2AR in isogenic hPSC-derived cardiomyocytes (2020)
Journal Article
Kondrashov, A., Mohd Yusof, N. A., Hasan, A., Goulding, J., Kodagoda, T., Hoang, D. M., …Denning, C. (2021). CRISPR/Cas9-mediated generation and analysis of N terminus polymorphic models of β2AR in isogenic hPSC-derived cardiomyocytes. Molecular Therapy - Methods and Clinical Development, 20, 39-53. https://doi.org/10.1016/j.omtm.2020.10.019

© 2020 During normal- and patho-physiological situations, the behavior of the beta2-adrenoreceptor (β2AR) is influenced by polymorphic variants. The functional impact of such polymorphisms has been suggested from data derived from genetic association... Read More about CRISPR/Cas9-mediated generation and analysis of N terminus polymorphic models of ?2AR in isogenic hPSC-derived cardiomyocytes.

Transfection of hPSC-Cardiomyocytes Using Viafect™ Transfection Reagent (2020)
Journal Article
Bodbin, S. E., Denning, C., & Mosqueira, D. (2020). Transfection of hPSC-Cardiomyocytes Using Viafect™ Transfection Reagent. Methods and Protocols, 3(3), Article 57. https://doi.org/10.3390/mps3030057

Twenty years since their first derivation, human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have shown promise in disease modelling research, while their potential for cardiac repair is being investigated. However, low transfection effic... Read More about Transfection of hPSC-Cardiomyocytes Using Viafect™ Transfection Reagent.

Mitochondrial DNA: Hotspot for Potential Gene Modifiers Regulating Hypertrophic Cardiomyopathy (2020)
Journal Article
Kargaran, P. K., Evans, J. M., Bodbin, S. E., Smith, J. G. W., Nelson, T. J., Denning, C., & Mosqueira, D. (2020). Mitochondrial DNA: Hotspot for Potential Gene Modifiers Regulating Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 9(8), Article 2349. https://doi.org/10.3390/jcm9082349

Hypertrophic cardiomyopathy (HCM) is a prevalent and untreatable cardiovascular disease with a highly complex clinical and genetic causation. HCM patients bearing similar sarcomeric mutations display variable clinical outcomes, implying the involveme... Read More about Mitochondrial DNA: Hotspot for Potential Gene Modifiers Regulating Hypertrophic Cardiomyopathy.

Blinded, multi-centre evaluation of drug-induced changes in contractility using human induced pluripotent stem cell-derived cardiomyocytes (2020)
Journal Article
Saleem, U., van Meer, B. J., Katili, P. A., Yusof, N. A. N. M., Mannhardt, I., Garcia, A. K., …Denning, C. (2020). Blinded, multi-centre evaluation of drug-induced changes in contractility using human induced pluripotent stem cell-derived cardiomyocytes. Toxicological Sciences, 176(1), 103–123. https://doi.org/10.1093/toxsci/kfaa058

Animal models are 78% accurate in determining whether drugs will alter contractility of the human heart. To evaluate the suitability of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for predictive safety pharmacology, we quan... Read More about Blinded, multi-centre evaluation of drug-induced changes in contractility using human induced pluripotent stem cell-derived cardiomyocytes.